Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022

ABSTRACT An outbreak of COVID-19 caused by the SARS-CoV-2 Omicron BA.2 sublineage occurred in Shanghai, China from February 26 to June 30, 2022. We use official reported data retrieved from Shanghai municipal Health Commissions to estimate the incidence of infections, severe/critical infections, and deaths to assess the disease burden. By adjusting for right censoring and RT-PCR sensitivity, we provide estimates of clinical severity, including the infection fatality ratio, symptomatic case fatality ratio, and risk of developing severe/critical disease upon infection. The overall infection rate, severe/critical infection rate, and mortality rate were 2.74 (95% CI: 2.73-2.74) per 100 individuals, 6.34 (95% CI: 6.02-6.66) per 100,000 individuals and 2.42 (95% CI: 2.23-2.62) per 100,000 individuals, respectively. The severe/critical infection rate and mortality rate increased with age, noted in individuals aged 80 years or older. The overall fatality ratio and risk of developing severe/critical disease upon infection were 0.09% (95% CI: 0.09-0.10%) and 0.27% (95% CI: 0.24-0.29%), respectively. Having received at least one vaccine dose led to a 10-fold reduction in the risk of death for infected individuals aged 80 years or older. Under the repeated population-based screenings and strict intervention policies implemented in Shanghai, our results found a lower disease burden and mortality of the outbreak compared to other settings and countries, showing the impact of the successful outbreak containment in Shanghai. The estimated low clinical severity of this Omicron BA.2 epidemic in Shanghai highlight the key contribution of vaccination and availability of hospital beds to reduce the risk of death.

[1]  Xiang Guo,et al.  Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death , 2022, BMC Medicine.

[2]  E. Lau,et al.  Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study , 2022, The Lancet Infectious Diseases.

[3]  M. Lipsitch,et al.  Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California , 2022, Nature Medicine.

[4]  M. Ajelli,et al.  Modeling transmission of SARS-CoV-2 Omicron in China , 2022, Nature Medicine.

[5]  Wenhong Zhang,et al.  Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic , 2022, The Lancet.

[6]  E. Lau,et al.  Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong, January–March 2022 , 2022, medRxiv.

[7]  R. Milo,et al.  Estimating disease severity of Omicron and Delta SARS-CoV-2 infections , 2022, Nature Reviews Immunology.

[8]  Ryan T Novak,et al.  COVID-19 Mortality and Vaccine Coverage — Hong Kong Special Administrative Region, China, January 6, 2022–March 21, 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[9]  D. He,et al.  Reduction in the infection fatality rate of Omicron variant compared with previous variants in South Africa , 2022, International Journal of Infectious Diseases.

[10]  E. Lau,et al.  Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong , 2022, medRxiv.

[11]  M. Exline,et al.  Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study , 2022, BMJ.

[12]  C. Viboud,et al.  SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020–21 , 2022, The Lancet Infectious Diseases.

[13]  S. Madhi,et al.  South African Population Immunity and Severe Covid-19 with Omicron Variant , 2022, The New England journal of medicine.

[14]  Georgia Salanti,et al.  Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis , 2020, medRxiv.

[15]  S. Merler,et al.  Probability of symptoms and critical disease after SARS-CoV-2 infection , 2020, 2006.08471.

[16]  Simon Cauchemez,et al.  Assessing the severity of the novel influenza A/H1N1 pandemic , 2009, BMJ : British Medical Journal.